Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The "Negotiation Skills for Contracts and Commercial Managers Training Course (Mar 16, 2026)" training has been added to ResearchAndMarkets.com's offering....
-
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming...
-
Imagine has announced over $11 million in strategic technology investments designed to further strengthen its production capabilities.
-
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
-
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Workforce Engagement Management, 2025" report has been added to ResearchAndMarkets.com's offering.A Benchmarking System to Spark...
-
AGMH secured $25M ELOC and convertible notes; funds fuel AI ASIC chip R&D and global supply chain development, advancing its AI industrial chain layout.
-
Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Understanding and Managing Contracts to Achieve Better Results Training Course (April 15-16, 2026)" training has been added to ...
-
Proprietary trading firm strengthens global footprint amid industry reset and shift away from challenge-based models
-
SAN FRANCISCO and SYDNEY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Fundbox, the leading provider of embedded capital infrastructure for small businesses, today announced its expansion into Australia,...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...